Armin has made over 16 trades of the Spectrum Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Armin exercised 7,500 units of SPPI stock worth $137,250 on 10 May 2018.
The largest trade Armin's ever made was selling 20,000 units of Spectrum Pharmaceuticals stock on 16 January 2018 worth over $574,200. On average, Armin trades about 3,681 units every 130 days since 2003. As of 10 May 2018 Armin still owns at least 138,493 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Armin Kessler stock trades at the bottom of the page.
Armin's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen y Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include: